Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RGNX Regenxbio

Pre-Mkt 03-11 05:53:14 EDT

9.90

-0.48

-4.62%

High10.77	Low9.87	Vol1.11M
Open10.35	D1 Closing10.38	Amplitude8.67%
Mkt Cap510.97M	Tradable Cap425.69M	Total Shares51.61M
T/O11.28M	T/O Rate2.59%	Tradable Shares43.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RGNX","market":"US","secType":"STK","nameCN":"Regenxbio","latestPrice":9.9,"timestamp":1773172800000,"preClose":10.38,"halted":0,"volume":1112456,"delay":0,"changeRate":-0.04624277456647403,"floatShares":42998600,"shares":51612984,"eps":-3.759292,"marketStatus":"Pre-Mkt","change":-0.48,"latestTime":"03-11 05:53:14 EDT","open":10.35,"high":10.77,"low":9.87,"amount":11279439.461687999,"amplitude":0.086705,"askPrice":10.03,"askSize":55,"bidPrice":8.25,"bidSize":42,"shortable":3,"etf":0,"ttmEps":-3.759292,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773235800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1442462400000,"exchange":"NASDAQ","adjPreClose":9.9,"postHourTrading":{"tag":"盘后","latestPrice":10.1,"preClose":9.9,"latestTime":"19:36 EDT","volume":5973,"amount":59176.15,"timestamp":1773185817684,"change":0.2,"changeRate":0.020202,"amplitude":0.020202},"volumeRatio":0.8667048053704648,"impliedVol":1.5782,"impliedVolPercentile":0.904},"requestUrl":"/m/hq/s/RGNX","defaultTab":"news","newsList":[{"id":"2618391679","title":"REGENXBIO Up Over 17%, on Track for Largest Percent Increase Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2618391679","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618391679?lang=en_us&edition=fundamental","pubTime":"2026-03-10 02:45","pubTimestamp":1773081900,"startTime":"0","endTime":"0","summary":"REGENXBIO, Inc.  is currently at $10.16, up $1.51 or 17.46%. --Would be highest close since Feb. 9, 2026, when it closed at $10.31. --On pace for largest percent increase since Nov. 7, 2024, when it rose 18.66%. --Down 87.63% from its all-time closing high of $82.15 on July 10, 2018. --Up 69.05% from 52 weeks ago , when it closed at $6.01. --Down 36.42% from its 52-week closing high of $15.98 on Jan. 22, 2026. --Up 91.34% from its 52-week closing low of $5.31 on April 8, 2025. --Traded as high as $10.76; highest intraday level since Feb. 6, 2026, when it hit $10.95. --Up 24.39% at today's intraday high; largest intraday percent increase since March 5, 2024, when it rose as much as 34.83%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"REGENXBIO Up Over 17%, on Track for Largest Percent Increase Since November 2024 -- Data Talk","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4505","RGNX","BK4139"],"gpt_icon":0},{"id":"2618794620","title":"LIVE MARKETS-Prasad's exit a win for biotechs, but don't celebrate yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2618794620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618794620?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:49","pubTimestamp":1773071361,"startTime":"0","endTime":"0","summary":"LIVE MARKETS-Prasad's exit a win for biotechs, but don't celebrate yetMain US stock indexes negative, but well off earlier lows; Nasdaq now off ~0.2%Financials weakest S&P 500 sector; Tech leads gaine","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL1N3ZX0RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314106906.USD","BK4585","LU0106831901.USD","LU1506573853.SGD","LU0980610538.SGD","LU0052756011.USD","BK4207","LU0162691827.USD","LU2360032135.SGD","LU1267930227.SGD","RGNX","LU0128525689.USD","LU0648001328.SGD","LU0072461881.USD","LU2236285917.USD","BK4505","LU0320765646.SGD","LU2456880835.USD","LU1201861249.SGD","LU2462157665.USD","LU2125154935.USD","LU1244550577.SGD","BK4559","IE00BSNM7G36.USD","LU1244550494.USD","LU1162221912.USD","LU0130517989.USD","BK4139","LU0310800965.SGD","LU1668664300.SGD","LU0477156953.USD","LU0098860793.USD","BK4534","BK4566","LU2125154778.USD","LU1791807156.HKD","LU0130102774.USD","BK4588","LU0170899867.USD","LU1244550221.USD","LU1366192091.USD","LU2417539215.USD","BK4563","BK4504"],"gpt_icon":0},{"id":"2618620753","title":"BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow","url":"https://stock-news.laohu8.com/highlight/detail?id=2618620753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618620753?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:46","pubTimestamp":1773071217,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, DowWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL6N3ZX16R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAL","HIMY","LYV","SATS","CAT","CDE","NEMG","XENE","AALG","HIMZ","IRON","JPMO","DTIL","DUK","COHX","NEM","HMYY","RGNX","AGH","PLD","VRT","CAPR","FCEL","XOMO","LITX","JEF","SATG","COP","DOW","NWMX","SLB","LUV","XOMZ","RLMD","PFE","NBP","DAL","HL","BAC","ITT","RAPP","DE","VRTL","XOMX","UAL"],"gpt_icon":1},{"id":"2618629228","title":"BUZZ-Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629228","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618629228?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:19","pubTimestamp":1773062349,"startTime":"0","endTime":"0","summary":"BUZZ-Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway** Shares of some biotech companies rise premarket as head of U.S. health regulator's vaccines and biologics unit Vinay Prasad set to leave the agency in April ** \"We believe his departure will lead to a much more favorable regulatory environment for certain companies such as Regenxbio RGNX.O\" - Clear Street** Shares of UniQure UQ1.F, Disc Medicine IRON.O, Capricor Therapeutics CAPR.O and Regenxbio climb between 1.5% and 35% in trading before the bell      ** \"Overall, we believe Dr. Prasad's departure is likely a tailwind for the biotech sector, particularly in cases of regulatory flexibility for companies developing novel therapies for rare diseases, but we would caution against celebrating before a replacement is disclosed\" - William Blair ** Truist analysts said while they expect his departure to be viewed positively by industry stakeholders, the overall outlook remains far from clear until it becomes ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4N3ZX1B2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","CAPR","BK4139","BK4505","BK4563","LU0053671581.USD","RGNX"],"gpt_icon":0},{"id":"2618462921","title":"This biotech's stock is soaring after a 'polarizing' FDA official is stepping down","url":"https://stock-news.laohu8.com/highlight/detail?id=2618462921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618462921?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:18","pubTimestamp":1773062280,"startTime":"0","endTime":"0","summary":"Shares of UniQure, which is developing a gene therapy for Huntington's disease, are rallying. Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down.UniQure's stock  was up 38% in premarket trading on Monday. Late Friday, the FDA told the Wall Street Journal that Vinay Prasad plans to leave the agency next month. He is the director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccines and rare-disease drugs.Prasad had reportedly been involved in the decision to request a new trial for uniQure's experimental gene therapy for Huntington's disease. UniQure's stock plunged on that request, falling 33% in a single day, and the action led to a broader discussion about the expertise of current FDA leadership and how rare-disease-focused biotechs have struggled to advance therapies under those leaders.\"Prasad was a polarizing figure as exemplified by his involvement in rare-disease drug regulatory reversals, an initial refusal  ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4534","BK4588","LU0109394709.USD","RGNX","BK4548","BK4563","MRNX","BK4532","BK4585","LU0889565916.HKD","BK4568","BK4581","MRNY","BK4551","BK4139","BK4533","QURE","BK4501","LU0320765992.SGD","XBI","BK4505"],"gpt_icon":1},{"id":"2618647160","title":"REGENXBIO Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647160?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:39","pubTimestamp":1773052740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:39 ET (10:39 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNX","BK4563","BK4505"],"gpt_icon":0},{"id":"2618647890","title":"Regenxbio price target lowered to $30 from $32 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647890?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:15","pubTimestamp":1773051330,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $30 from $32 and keeps a Buy rating on the shares following the Q4 report. P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-30-from-32-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-30-from-32-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNX"],"gpt_icon":0},{"id":"2617652837","title":"RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2617652837","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617652837?lang=en_us&edition=fundamental","pubTime":"2026-03-07 14:01","pubTimestamp":1772863294,"startTime":"0","endTime":"0","summary":"RegenXBio Inc. (RGNX) has disclosed a new risk, in the Innovation / R&D category. RegenXbio Inc. faces heightened development and regulatory risk b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regenxbio-faces-fda-clinical-holds-heightened-development-risk-potential-delays-and-investor-uncertainty?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regenxbio-faces-fda-clinical-holds-heightened-development-risk-potential-delays-and-investor-uncertainty?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","RGNX","BK4139","BK4563"],"gpt_icon":0},{"id":"2617663132","title":"REGENXBIO Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663132","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617663132?lang=en_us&edition=fundamental","pubTime":"2026-03-07 00:04","pubTimestamp":1772813040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 11:04 ET (16:04 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","RGNX","BK4563"],"gpt_icon":0},{"id":"2617574720","title":"Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617574720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617574720?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:40","pubTimestamp":1772750407,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on RegenXBio (RGNX – Research Report) and Kura Oncology...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-regenxbio-rgnx-and-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-regenxbio-rgnx-and-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4585","LABU","BK4563","BK4505","BK4137","BK4581","LU0029874061.USD","RGNX","BK4588","XBI","HCSG","KURA","XLV","BK4139"],"gpt_icon":0},{"id":"2617573493","title":"Regenxbio price target lowered to $17 from $18 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2617573493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617573493?lang=en_us&edition=fundamental","pubTime":"2026-03-06 04:15","pubTimestamp":1772741732,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Regenxbio (RGNX) to $17 from $18 and keeps an Overweight rating on the shares after the company r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-17-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-17-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNX"],"gpt_icon":0},{"id":"2617784905","title":"Regenxbio price target lowered to $42 from $45 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2617784905","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617784905?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:15","pubTimestamp":1772738121,"startTime":"0","endTime":"0","summary":"Stifel lowered the firm’s price target on Regenxbio (RGNX) to $42 from $45 and keeps a Buy rating on the shares. The firm notes the company is movi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-42-from-45-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-42-from-45-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNX","SF"],"gpt_icon":0},{"id":"2617052191","title":"BUZZ-Regenxbio falls as Q4 loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2617052191","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617052191?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:10","pubTimestamp":1772727056,"startTime":"0","endTime":"0","summary":"BUZZ-Regenxbio falls as Q4 loss widens** Shares of drug developer Regenxbio RGNX.O fall 8.32% to $8.38 ** Co posts Q4 loss of $1.30 per share, versus loss of $1.01 per share a year ago. Analysts were expecting a loss of 96 cents per share, according to data compiled by LSEG ** Posts Q4 revenue of $30.3 million, below analysts' estimate of $36.6 million** R&D expenses for the quarter were $59.6 million, due to higher clinical trial expenses and manufacturing-related costs - RGNX** RGNX shares had risen over 86% in 2025   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL4N3ZT1KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4563","RGNX"],"gpt_icon":0},{"id":"2617526207","title":"Regenxbio Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617526207","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617526207?lang=en_us&edition=fundamental","pubTime":"2026-03-05 23:12","pubTimestamp":1772723536,"startTime":"0","endTime":"0","summary":"Regenxbio Inc reports results for the quarter ended December 31 - Earnings SummaryRegenxbio Inc RGNX.OQ reported a quarterly adjusted loss of $1.30 per share for the quarter ended December 31, lower t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL8N3ZT1T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNX","BK4563","BK4505"],"gpt_icon":0},{"id":"2617854488","title":"Regenxbio Q4 revenue rises but loss widens as costs increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2617854488","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617854488?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:13","pubTimestamp":1772712828,"startTime":"0","endTime":"0","summary":"Regenxbio Q4 revenue rises but loss widens as costs increaseOverviewBiotech firm's Q4 revenue rose to $30.3 mln, driven by collaborations and royaltiesNet loss for Q4 widened to $67.1 mln from $51.2 m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL1N3ZT0L0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","RGNX","BK4505","BK4139"],"gpt_icon":0},{"id":"2617541209","title":"Regenxbio Q4 R&D expenses rise 18.3% to USD 59.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541209","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541209?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:06","pubTimestamp":1772712364,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire  on March 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL451Vjl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","LU0203345920.USD","BK4588","LU1267930573.SGD","IE00B2B36J28.USD","SG9999015945.SGD","IE00B4R5TH58.HKD","LU0256863811.USD","LU0965508806.USD","BK4563","IE00B19Z3581.USD","LU2129689431.USD","LU2237443622.USD","BK4585","LU1989772840.SGD","IE0002141913.USD","LU0795875169.SGD","LU1430594728.SGD","LU0511384066.AUD","LU0553294199.USD","LU0114720955.EUR","LU2237443465.HKD","LU1839511570.USD","LU0912757837.SGD","LU0949170772.SGD","LU0432979614.USD","LU0985320562.USD","SG9999015986.USD","LU1585245621.USD","LU0289739343.SGD","LU0289739699.SGD","IE00BN8TJ469.HKD","LU0170899867.USD","LU0289961442.SGD","LU2129689605.HKD","LU0057025933.USD","LU2237443895.HKD","RGNX","LU0708994859.HKD","ABBV","LU1934455863.HKD","IE0009355771.USD","LU0234570918.USD","BK4550","LU2023251221.USD","LU1291159041.SGD","SG9999015952.SGD","LU2089984988.USD","SG9999015978.USD","LU0029864427.USD"],"gpt_icon":0},{"id":"2617541224","title":"BRIEF-Regenxbio Q4 License & Royalty Revenue USD 27.148 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541224","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541224?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:05","pubTimestamp":1772712345,"startTime":"0","endTime":"0","summary":"BRIEF-Regenxbio Q4 License & Royalty Revenue USD 27.148 Million\n\n\nMar 05 (Reuters) - Regenxbio Q4 net income USD -67.149 million.\n\nQ4 operating expenses USD 87.973 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLX21DD90:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4505","BK4563","BK4139"],"gpt_icon":0},{"id":"2617292541","title":"Regenxbio Q4 Operating Expenses USD 87.973 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617292541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617292541?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:05","pubTimestamp":1772712300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLX21DD90:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","BK4563","RGNX"],"gpt_icon":0},{"id":"2617412915","title":"Regenxbio Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2617412915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617412915?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:05","pubTimestamp":1772712300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA2F08KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNX","BK4505","BK4139","BK4563"],"gpt_icon":0},{"id":"2616088532","title":"REGENXBIO to Present RGX-202 Duchenne Gene Therapy Data at MDA Clinical and Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616088532","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616088532?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:05","pubTimestamp":1772625920,"startTime":"0","endTime":"0","summary":"REGENXBIO Inc. will present preclinical and interim Phase I/II clinical data on its investigational Duchenne muscular dystrophy gene therapy RGX-202 at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference in Orlando, Florida, March 8-11, 2026, including a podium presentation on March 11, 2026 at 11:45 a.m. ET and a poster presentation. The company will also host a symposium, “Advancing Duchenne Gene Therapy Trials in a New Era: Optimizing Design and Interpretation,” on March 9, 2026 at 12 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL5nWGkK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNX","BK4505","BK4563"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regenxbio.com","stockEarnings":[{"period":"1week","weight":0.1392},{"period":"1month","weight":-0.0416},{"period":"3month","weight":-0.242},{"period":"6month","weight":0.0432},{"period":"1year","weight":0.6473},{"period":"ytd","weight":-0.3125}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0195},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0297},{"period":"1year","weight":0.208},{"period":"ytd","weight":-0.007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.091067},{"month":2,"riseRate":0.272727,"avgChangeRate":0.000501},{"month":3,"riseRate":0.636364,"avgChangeRate":0.022489},{"month":4,"riseRate":0.6,"avgChangeRate":0.035795},{"month":5,"riseRate":0.3,"avgChangeRate":-0.022478},{"month":6,"riseRate":0.6,"avgChangeRate":0.047674},{"month":7,"riseRate":0.4,"avgChangeRate":-0.001741},{"month":8,"riseRate":0.4,"avgChangeRate":0.017624},{"month":9,"riseRate":0.6,"avgChangeRate":0.07131},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.060741},{"month":11,"riseRate":0.727273,"avgChangeRate":0.164969},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.05132}],"exchange":"NASDAQ","name":"Regenxbio","nameEN":"Regenxbio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regenxbio,RGNX,Regenxbio股票,Regenxbio股票老虎,Regenxbio股票老虎国际,Regenxbio行情,Regenxbio股票行情,Regenxbio股价,Regenxbio股市,Regenxbio股票价格,Regenxbio股票交易,Regenxbio股票购买,Regenxbio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction